广东东方昆仑(东莞)律师事务所 关于 惠州市锦好医疗科技股份有限公司 2024 年度股东会 之 法律意见书 广东东方 昆仑(东莞)律师事务所 KUN LUN DONGGUAN LAW FIRM 二〇二五年五月 广东东方昆仑(东莞)律师事务所 关于 惠州市锦好医疗科技股份有限公司 2024 年度股东会 KUNLUN 致:惠州市锦好医疗科技股份有限公司 广东东方昆仑(东莞)律师事务所(下称"本所")接受惠州市锦好医疗科 技股份有限公司(下称"公司")的委托,并根据《中华人民共和国公司法》(下 称"《公司法》")、《中华人民共和国证券法》(下称"《证券法》")、《上 市公司股东会规则(2025年修订)》(下称"股东会规则")、《上市公司信 息披露管理办法》(下称"信息披露管理办法")等中华人民共和国(下称"中 国",为本法律意见书之目的,不包括香港特别行政区、澳门特别行政区和台湾 地区)的法律、行政法规、规章和规范性文件(下称"法律、法规、规范性文件") 以及现行有效的《惠州市锦好医疗科技股份有限公司章程》(下称"《公司章程》") 的有关规定,指派本所律师黄瑞平律师、赖华敏律师出席公司 2024年度股东会 (下称" ...

惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 第三届董事会第九次会议，会议审议通过《关于回购注销 2022 年股权激励计划部分 限制性股票的议案》，该议案已经 2025 年 5 月 22 日召开的 2024 年年度股东会审议 通过。 根据《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引 第 3 号——股权激励和员工持股计划》（以下简称"《监管指引第 3 号》"）等法律法 规、规范性文件以及《惠州市锦好医疗科技股份有限公司章程》《2022 年股权激励计 划（草案）》（以下简称"《激励计划（草案）》"）的有关规定，需回购注销第三个 解除限售期解限售条件未成就，已获授但尚未解除限售的 47.6 万股限制性股票，公司 将对上述激励对象持有的已获授但尚未解除限售的合计 47.6 万股限制性股票予以回 购注销，公司的注册资本将相应减少。 二、需债权人知晓的相关信息 公司于 2025 年 5 月 22 日召开的 2024 年年度股东会审议通过了《关于减少注册 资本暨修订公司章程的议案》。 本次限制性股票回购注销完成后公司总股本由原 97,686,643 股变更为 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2025-050 4.会议召集人：董事会 5.会议主持人：王敏先生 惠州市锦好医疗科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 22 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议与网络投票相结合的方式召开 6.召开情况合法合规的说明： 2025 年 4 月 18 日，公司召开第三届董事会第九次会议审议通过《关于提请 召开 2024 年度股东会的议案》，并于 2025 年 4 月 22 日在北京证券交易所信息披 露平台（http://www.bse.cn/）刊登了本次股东会的通知公告。 （二）会议出席情况 出席和授权出席本次股东会的股东共 7 人，持有表决权的股份总数 62,481,306 股，占公司有表决权股份总数的 64.5230%。 其中通过网络投票参与本次股东会的股东共 1 人，持有表决权的股份 ...

Group 1: New Product Launches - Huawei launched nova 14 series and MateBook Fold, featuring the world's largest dual-layer OLED display[1] - Xiaomi introduced the new flagship Xiaomi 15S Pro and the 3nm flagship chip,玄戒 O1, with a transistor count of 19 billion[1][17] Group 2: Market Capitalization - Total market capitalization of 24 consumer electronics companies on the North Exchange reached 76.078 billion yuan as of May 23, 2025[21] - Total market capitalization of 16 semiconductor-related companies on the North Exchange reached 60.768 billion yuan as of May 23, 2025[24] Group 3: Industry Performance - Average decline in five major industries: high-end equipment (-4.32%), information technology (-5.02%), chemical new materials (-3.88%), consumer services (-4.27%), and pharmaceutical biology (-2.37%) for the week[2][27] - The median P/E ratio for the electronic industry increased to 64.9X, while the median P/E for the smart manufacturing industry decreased to 45.3X[41][48] Group 4: Investment Announcements - Haitai New Energy plans to invest approximately 600 million yuan in a new 2GW solar cell and 1GW module project in Indonesia[4][63]

Group 1: Company Certifications and Capabilities - The company has obtained multiple certifications including FDA510(k), EU MDR, ISO9001, ISO13485, and others, enabling it to meet global market entry requirements [5] - The company holds a medical device production license and registration certificate, ensuring compliance with industry standards [5] Group 2: Cost Control Measures - Current cost control measures include self-developed chip applications, production process optimization, and efficiency improvements [6] - Future plans to reduce costs involve assimilating technology from the acquisition of Intricon, promoting modular product design, and implementing budget control [6] Group 3: Competitive Advantages and Strategies - The company has established a vertical layout in the hearing aid industry, focusing on chip design, algorithm research, and channel development [7] - The technical team has mastered core technologies such as DSP digital hearing aid chip design and sound processing algorithms, providing a competitive edge [7] Group 4: Financial Performance and Growth - In 2024, the company experienced a 49% decline in profit due to increased sales expenses from expanding its own brand channels [8] - The first quarter of the current year showed significant growth in self-owned brand sales revenue, indicating early success from the previous year's channel expansion [8] Group 5: Research and Development Plans - The company plans to maintain reasonable R&D investment intensity based on project progress [9] - There are plans to enhance operational efficiency in offline stores and adapt to market changes for store expansion [9] Group 6: Customer Base and Order Acquisition - The customer base has expanded to include new overseas supermarket channels for self-owned brands, while new order acquisition remains stable [10] - The company continues to focus on its existing B-end customer base while integrating new clients [10] Group 7: Core Business Advantages - The establishment of the subsidiary Chip Sea Ling in 2020 has enabled the development of self-researched DSP digital hearing aid chips, which significantly reduce manufacturing costs [11] - The company has achieved mass production of its first-generation self-developed chip, with approximately 780,000 units integrated into products [12]

证券代码：872925 证券简称：锦好医疗 公告编号：2025-047 惠州市锦好医疗科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、说明会类型 惠州市锦好医疗科技股份有限公司（以下简称"公司"）2025 年 4 月 22 日 在北京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》（公 告编号：2025-010）及《2024 年年度报告摘要》（公告编号：2025-011），为方 便广大投资者更深入了解公司 2024 年度经营业绩的具体情况，加强与投资者 的交流互动，公司拟召开 2024 年年度报告业绩说明会。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 20 日（星期二）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络方式召开，投资者可登陆中证网"中 证路演中心"（https://www.cs.com.cn/roadshow/yjsmh/）参与本次年报业绩说明 ...

关于 2025 年第一次临时股东会延期公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 会议召开基本情况 （一） 股东会届次 本次会议为 2025 年第一次临时股东会。 证券代码：872925 证券简称：锦好医疗 公告编号：2025-048 惠州市锦好医疗科技股份有限公司 （二） 股东会股权登记日 延期召开的股东会的股权登记日为 2025 年 5 月 23 日。 其他相关事项参照公司 2025 年 5 月 14 日披露的公告，公告编号：2025-044。 四、 其他 二、 延期召开股东会原因 公司原定于 2025 年 5 月 29 日召开 2025 年第一次临时股东会，因公司主要股东及 部分董事会成员的重要工作安排与股东会时间冲突，为确保股东会的顺利召开及全体股 东充分参与，经公司慎重研究决定，将股东会延期至 2025 年 6 月 4 日召开。除会议时 间变更外，会议地点、股权登记日、召开方式、审议事项及登记方式等其他事项均保持 不变。此次延期是为了更好地协调公司内部工作安排，确保股东会的筹备工 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

中信建投证券股份有限公司 关于惠州市锦好医疗科技股份有限公司 向不特定合格投资者公开发行股票之保荐工作总结报告书 中信建投证券股份有限公司（以下简称"中信建投"或"保荐机构"）作为 惠州市锦好医疗科技股份有限公司（以下简称"锦好医疗"、"公司"或"发行 人"）向不特定合格投资者公开发行股票（以下简称"本次发行"）的保荐机构， 履行持续督导职责期限至 2024 年 12 月 31 日。目前，本次发行持续督导期限已 经届满，根据《证券发行上市保荐业务管理办法》《北京证券交易所证券发行上 市保荐业务管理细则》《北京证券交易所股票上市规则》等法规和规范性文件要 求，保荐机构出具本保荐工作总结报告书。 二、保荐工作概述 （一）尽职推荐工作 发行人名称 惠州市锦好医疗科技股份有限公司 证券代码 872925 注册资本 9,768.6643 万元 注册地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 主要办公地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 法定代表人 王敏 实际控制人 王敏、王芳 联系电话 0752-3266781 本次证券发行类型 向不特定合格投资者公开发行股票并 ...